UB Paderborn / Katalog / Suche / in CDI

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

The New England journal of medicine, 2018-02, Vol.378 (7), p.615-624

2018

Volltextzugriff (PDF)

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

The American heart journal, 2010-10, Vol.160 (4), p.635-641.e2

2010

Volltextzugriff (PDF)

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

The Lancet (British edition), 2015-06, Vol.385 (9984), p.2288-2295

2015

Volltextzugriff (PDF)

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

The New England journal of medicine, 2013-11, Vol.369 (22), p.2093-2104

2013

Volltextzugriff (PDF)

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

Journal of clinical pharmacology, 2011-05, Vol.51 (5), p.687-694

2011

Volltextzugriff (PDF)

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48

European heart journal, 2014-06, Vol.35 (22), p.1457-1465

2014

Volltextzugriff (PDF)

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

Journal of the American Heart Association, 2016-02, Vol.5 (2), p.n/a

2016

Volltextzugriff (PDF)

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

Thrombosis and haemostasis, 2012-05, Vol.107 (5), p.925

2012

Volltextzugriff (PDF)

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study

Thrombosis and haemostasis, 2010-09, Vol.104 (3), p.642

2010

Volltextzugriff (PDF)

Mortality in Patients With Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial

The American journal of medicine, 2016-08, Vol.129 (8), p.850-857.e2

2016

Volltextzugriff (PDF)

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Journal of cardiovascular pharmacology, 2013-08, Vol.62 (2), p.212-221

2013

Volltextzugriff (PDF)

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

Research and practice in thrombosis and haemostasis, 2022-07, Vol.6 (5), p.e12748-n/a, Article e12748

2022

Volltextzugriff (PDF)

Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin

Research and practice in thrombosis and haemostasis, 2021-07, Vol.5 (5), p.e12566-n/a, Article e12566

2021

Volltextzugriff (PDF)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British journal of clinical pharmacology, 2016-12, Vol.82 (6), p.1591-1600

2016

Volltextzugriff (PDF)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013-10, Vol.13 (5), p.331-342

2013

Volltextzugriff (PDF)

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

European heart journal, 2019-05, Vol.40 (19), p.1541-1550

2019

Volltextzugriff (PDF)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

European heart journal, 2023-04, Vol.44 (14), p.1231-1244

2023

Volltextzugriff (PDF)

Impact of Thrombocytopenia on Bleeding and Recurrent Thrombosis in Cancer Associated Thrombosis: A Post Hoc Analysis of Hokusai VTE Cancer Study

Blood, 2022-11, Vol.140 (Supplement 1), p.5675-5676

2022

Volltextzugriff (PDF)

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin

British journal of clinical pharmacology, 2013-04, Vol.75 (4), p.966-978

2013

Volltextzugriff (PDF)

Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial

The American heart journal, 2018-11, Vol.205, p.63-69

2018

Volltextzugriff (PDF)

Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain

Clinical therapeutics, 2006, Vol.28 (1), p.86-98

2006

Volltextzugriff (PDF)

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48

European journal of heart failure, 2016-09, Vol.18 (9), p.1153-1161

2016

Volltextzugriff (PDF)

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Hypertension (Dallas, Tex. 1979), 2019-09, Vol.74 (3), p.597-605

2019

Volltextzugriff (PDF)

Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination

Journal of cardiovascular pharmacology, 2012-10, Vol.60 (4), p.335

2012

Volltextzugriff (PDF)

Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial

Thrombosis research, 2020-11, Vol.195, p.209-214

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study

Mortality in Patients With Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

Impact of Thrombocytopenia on Bleeding and Recurrent Thrombosis in Cancer Associated Thrombosis: A Post Hoc Analysis of Hokusai VTE Cancer Study

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin

Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial

Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination

Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial

Aktive Filter

Suchergebnisse filtern